N/A N=84 Effect of Chicken Egg Antibody (IgY) on Patients With Chronic Gastritis
Chronic Gastritis Caused by Helicobacter Pylori
Primary: UBT Values at Baseline and 8 Weeks — 161.64; 158.54; 49.42; 73.37 UBT value
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=232 Comparison of Sequential or Concomitant Therapy for Helicobacter Pylori Infection
Helicobacter Infection
Primary: Number of Participants in Which H. Pylori Was Eradicated — 92; 95 participants
N/A N=45 Clinical Experiment of Helicobacter Pylori Transmission
Infection · Achlorhydria
Primary: Development of Diarrhea — 5; 6 participants
N/A N=1,490 Blood Tests for Gastritis and Gastric Neoplasms
Cancer Screening Tests
Primary: Significant Blood Test Findings Correlated With Gastric Neoplasms — 9.9; 6.5 score on a scale
Phase 2 N=40 Helicobacter Pylori Eradication in Non-diabetic Non-alcoholic Steatohepatitis
Non-alcoholic Fatty Liver Disease
Primary: Liver Fat Content — 8.38; 7.72; 8.50; 7.29 percentage of liver fat content — p=0.94
Phase 4 N=240 Sequential and Hybrid Therapies for H Pylori Infection
Helicobacter Pylori Infection
Primary: Number of Participants in Which H. Pylori Was Eradicated — 94; 99 participants
N/A N=70 Lactobacillus Reuteri in Management of Helicobacter Pylori Infection in Dyspeptic Patients
Helicobacter Pylori Infection
Primary: Eradication of H Pylori Infection 4 Weeks After Completion of Therapy — 23; 26 participants
Phase 4 N=307 Concomitant, Sequential, and Standard Triple Therapy for H. Pylori Infection
Helicobacter Pylori Infection
Primary: Number of Participants With Complete Eradication of Helicobacter Pylori — 102; 100; 101 participants
N/A N=219 The Efficacy of the Tailored Therapy Based on Antimicrobial Susceptibility for 2nd Eradication of H. Pylori
Helicobacter Infection
Primary: Number of Participants in Each Arm/Group With Successful H. Pylori Eradication — 67; 63; 36 participants
Phase 3 N=119 ERADICATE Hp - Treating Helicobacter Pylori With RHB-105
Dyspepsia · Helicobacter Pylori Infection
Primary: The Occurrence of H. Pylori Eradication as Confirmed Via 13C UBT Testing — 59; 1; 7; 36 Participants — p=0.001
Phase 3 N=455 ERADICATE Hp2 - Treating Helicobacter Pylori With RHB-105 Compared to Active Comparator
Helicobacter Pylori Infection · Dyspepsia
Primary: Number of Participants With Eradication of H. Pylori — 191; 131 Participants — p=0.0001
Phase 1 N=44 A Study of Vonoprazan in Adults With Helicobacter Pylori
Helicobacter Pylori
Primary: Cmax: Maximum Observed Plasma Concentration for Bismuth — 42.8; 32.9 nanogram per milliliter (ng/mL)
N/A N=54 Efficacy and Safety of Hizikia Fusiformis Extract in Subjects Showing Erosive Gastritis
Erosive Gastritis
Primary: Changes in Erosions — 4.36; 3.38; 2.32; 2.43 erosions
Phase 4 N=924 Clarithromycin Resistant Tailored Therapy
Peptic Ulcer · Helicobacter Pylori Infection
Primary: Helicobacter Pylori Eradication Rate — 75.9; 91.2; 79.1 percentage of participants
Phase 2 N=40 Helicobacter Pylori Eradication in Diabetic Subjects With Non-alcoholic Fatty Liver Disease
Non-alcoholic Fatty Liver Disease
Primary: Liver Fat Content Change From Baseline to Six Weeks Post H.Pylori Treatment — 2.46; 3.61 percentage of liver fat content
Phase 4 N=305 Esomeprazole Treatment Co-diagnosed Non Erosive Reflux Disease (NERD) and Chronic Gastritis Patients
Non Erosive Reflux Disease · Chronic Gastritis
Primary: Symptom Control Rate at 24 Weeks Assessed by Gerd Q Questionnaire. — 94.9; 87.3 percentage of participants
N/A N=88 Anti-Helicobacter Pylori Antibodies (IgG) in Serum of Women With Unexplained Infertility
Infertility, Female
Primary: Quantitative Helicobacter Pylori IgG Assay in Serum — 70; 70 arbitrary unit per millilitre — p=<0.001
Phase 3 N=40 Rifaximin Associated With Classic Triple Therapy for the Eradication of Helicobacter Pylori Infection
Bacterial Infection Due to Helicobacter Pylori (H. Pylori)
Primary: Percentage of Participants With H.Pylori Infection Eradication — 61 percentage of participants
Phase 3 N=440 Efficacy and Safety of Quadruple Therapy in Eradication of H. Pylori: A Comparison to Triple Therapy
Helicobacter Infections
Primary: Helicobacter Pylori Eradication Confirmed by Urea Breath Test — 166; 112 Participants
Phase 4 N=301 Post-marketing Clinical Study of Rebamipide in Patients With Gastric Ulcer
Stomach Ulcer
Primary: Gastric Ulcer Healing Rate (Number of Subjects Whose Gastric Ulcer Was Healed/Number of Subjects Evaluated x 100) at Week 8 — 70.13; 60.54 percentage of participants
Phase 4 N=123 13-C Urea Breath Test Using BreathID System and PPIs (Proton Pump Inhibitors)
Helicobacter Pylori Infection
Primary: Urea Breath Test Result (DOB > 5 is Positive)After Different Time Periods From When PPI (Proton Pump Inhibitor) Was Stopped. — 1; 3; 1; 0 participants
Phase 3 N=1,046 Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Helicobacter Pylori Infection
Helicobacter Pylori Infection
Primary: Percentage of Participants With Successful Helicobacter Pylori (H Pylori) Eradication in Participants Without a Clarithromycin- or Amoxicillin-resistant Strain of H…
N/A N=164 Levofloxacin-containing Therapies In Second Line Helicobacter Pylori Eradication
Helicobacter Pylori Infection
Primary: Percentage of Participants With Successful Eradication of H. Pylori — 91.4; 81.5 percentage of eradication
N/A N=330 Comparison of Hybrid and Bismuth Quadruple Therapies for Helicobacter Pylori Eradication
Helicobacter Pylori Infection
Primary: Number of Participants in Which H. Pylori Was Eradicated — 154; 154 participants
N/A N=440 Comparison of 12-day Reverse Hybrid Therapy and 12-day Standard Triple Therapy for Helicobacter Pylori Infection
Helicobacter Pylori Infection
Primary: Number of Participants in Which H. Pylori Was Eradicated — 206; 191 participants — p=<0.05
Phase 4 N=14 Effects of Gastric Acid on Colonic Microbiome
Clostridium Difficile
Primary: Shannon Diversity Index Measuring Change in Microbiome Diversity — 0.18; 0.14 Shannon index — p=0.71
Phase 3 N=510 A Study to Evaluate the Efficacy and Safety of Bismuth-Containing Quadruple Therapy With Oral Vonoprazan (TAK-438) 20 mg Compared to Esomeprazole 20 mg Twice Daily in Paticipants With Helicobacter Pylori Infection
Helicobacter Pylori
Primary: Percentage of Helicobacter Pylori Positive (HP+) Participants With Successful HP Eradication at Week 4 Post-Treatment — 86.8; 86.7 percentage of participants — p==0.0009
N/A N=390 Compare Sequential and Quadruple Therapy for the Eradication of Helicobacter Pylori in Korea
Helicobacter Pylori Infection
Primary: Counts of Participants With Successful H. Pylori Eradication — 146; 134 Participants
Phase 2 N=73 Inhibition of Gastric Acid is the Key to Satisfactory Relief of Symptoms With Esomeprazole in NUD Patients
Indigestion
Primary: Percentage of Participants With Satisfactory Relief of Non-ulcer Dyspepsia Symptoms — 71; 34; 82; 56 percentage of participants
Phase 4 N=112 High Dose Dual Therapy vs Clarithromycin Triple Therapy for Treatment Naive H Pylori Infection in an Urban Population
Helicobacter Pylori Infection
Primary: Number of Participant With Eradication of Disease — 37; 42 Participants